The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
Kao
嘻嘻哈哈
Criminology34
Copyright
GingerF
无极微光
ricardo
OK
youtianyi
潇洒柏柳
lizishu
cnspower
cdercder
爆爆
贪玩的秋柔
烟消云散
Kelley
强健的面包
核桃
richard
皖公网安备34019202002308
